Literature DB >> 8539394

Early-stage breast cancer: arm edema after wide excision and breast irradiation.

K D Kiel1, A W Rademacker.   

Abstract

PURPOSE: To determine the incidence of arm edema in women with early-stage breast cancer after breast-conserving surgery and irradiation.
MATERIALS AND METHODS: Women aged 29-83 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) underwent a series of measurements of the circumference of each arm. Patient and treatment factors were analyzed for predictive value.
RESULTS: Arm edema developed in 35.0% (n = 64), and clinically significant edema developed in 17.5% (n = 32) of patients. Dissections that yielded 16 or more nodes led to a 44% actuarial incidence of edema and a 29% actuarial incidence of clinically significant edema. Clinically significant arm changes occurred in 19 of the 87 (22%) women older than 55 years and in 13 of the 96 (14%) women younger than 55 years (P = .002). Chemotherapy, breast radiation dose, and use of tamoxifen had no effect on development of edema.
CONCLUSION: Axillary dissection producing more than 15 nodes and age older than 55 years are predictive of arm edema.

Entities:  

Mesh:

Year:  1996        PMID: 8539394     DOI: 10.1148/radiology.198.1.8539394

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

Review 1.  The new era of the lymphatic system: no longer secondary to the blood vascular system.

Authors:  Inho Choi; Sunju Lee; Young-Kwon Hong
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy.

Authors:  Imari Deura; Muneaki Shimada; Keiko Hirashita; Maki Sugimura; Seiya Sato; Shinya Sato; Tetsuro Oishi; Hiroaki Itamochi; Tasuku Harada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2014-07-04       Impact factor: 3.402

3.  Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.

Authors:  Stephanie M Cohen; Ridhwi Mukerji; Shuang Cai; Ivan Damjanov; M Laird Forrest; Mark S Cohen
Journal:  Am J Surg       Date:  2011-10-08       Impact factor: 2.565

4.  Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study.

Authors:  Rehana L Ahmed; Kathryn H Schmitz; Anna E Prizment; Aaron R Folsom
Journal:  Breast Cancer Res Treat       Date:  2011-07-15       Impact factor: 4.872

5.  Ultrasonographic Evaluation of Breast Cancer-related Lymphedema.

Authors:  Yumi Jeon; Jaewon Beom; Soyoung Ahn; Soo-Kyung Bok
Journal:  J Vis Exp       Date:  2017-01-12       Impact factor: 1.355

6.  The role of occupational upper extremity use in breast cancer related upper extremity lymphedema.

Authors:  Gulgun Tahan; Ronald Johnson; Lisa Mager; Atilla Soran
Journal:  J Cancer Surviv       Date:  2009-12-06       Impact factor: 4.442

7.  Surgeon specialization and use of sentinel lymph node biopsy for breast cancer.

Authors:  Tina W F Yen; Purushuttom W Laud; Rodney A Sparapani; Ann B Nattinger
Journal:  JAMA Surg       Date:  2014-02       Impact factor: 14.766

8.  Diagnosis and treatment of lymphedema after breast cancer: a population-based study.

Authors:  Oksana Sayko; Liliana E Pezzin; Tina W F Yen; Ann B Nattinger
Journal:  PM R       Date:  2013-05-17       Impact factor: 2.298

9.  Level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy: a retrospective study.

Authors:  R V Bhargavan; A Mirza; K Cherian; J Krishna; P Augustine
Journal:  Ann R Coll Surg Engl       Date:  2019-11-22       Impact factor: 1.891

10.  Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work?

Authors:  Atilla Soran; Ebru Menekse; Mark Girgis; Lori DeGore; Ronald Johnson
Journal:  Support Care Cancer       Date:  2015-09-09       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.